News | March 11, 2008| Cristen C. Bolan

Avoid Interventional Overload with ACC FastPass

Cristen C. Bolan, Editor, Diagnostic & Invasive Cardiology

This may be the Red Bull of interventional cardiology sessions, since The Society of Cardiovascular Angiography and Interventions (SCAI) and ACC’s Innovation in Intervention: i2 Summit joined forces to form the “SCAI-ACCi2” meeting.
You might need a few energy drinks to keep up with this interventional power pack, which runs concomitantly with ACC.08. Sessions will feature live case transmissions, highlight emerging technologies, provide case reviews on IVUS, left main, CTO, valvular and structural procedures, bifurcation and endovascular procedures, and opinions can be voiced in debates covering COURAGE, PCI versus CABG, DES selection, embolic protection, vulnerable plaque, IIb/IIIa inhibitors, PFO closure for stroke, elective PCI and carotid stenting in asymptomatic patients.
But before your heart starts racing from either the caffeine or in anticipation of all there is to see and do, conference organizers promise to recreate that same intimate feel and collegial interaction of the SCAI meeting.
Just in case, Diagnostic & Invasive Cardiology will help control information overload by streamlining the data for you on our ACC FastPass found at www.DIcardiology.net. ACC FastPass delivers updates on case reviews and debates, keynotes and new technology roll outs before, during and after ACC, and presents it to you in a more manageable package, so you’ll have energy enough to get all of the info you need.

Related Content

FDA Approves Six-Month Primary Endpoint for Tack Endovascular System in Below the Knee Disease
News | Stents Peripheral| July 14, 2017
Intact Vascular Inc. announced the U.S. Food and Drug Administration (FDA) approved an Investigational Device Exemption...
Onyx DES 2.0 mm stent meets primary endpoints in small vessels
News | June 12, 2017
June 12, 2017 – The Medtronic Resolute Onyx Drug-Eluting Stent (DES) met its primary endpoint of target lesion failur
First Pennsylvania Patient Treated in LEADERS FREE II Trial of BioFreedom Drug-Coated Stent
News | Stents Drug Eluting| May 12, 2017
PinnacleHealth CardioVascular Institute enrolled the first patient in Pennsylvania in a trial assessing the safety and...
Resolute Onyx DES, drug eluting stent, medtronic, gains FDA approval
Technology | Stents Drug Eluting| May 01, 2017
May 1, 2017 — The U.S.
Sponsored Content | Videos | Stents Drug Eluting| May 01, 2017
This video, provided by Medtronic, demonstrates the Resolute Onyx coronary stent.
Tryton Medical, Side Branch Stent, first U.S. commercial case, New York-Presbyterian Hospital, Columbia University Medical Center
News | Stents Bifurcation| March 31, 2017
Tryton Medical Inc. recently announced that the first U.S. commercial case using the Tryton Side Branch Stent was...
Sponsored Content | Videos | Stents Bioresorbable| March 30, 2017
Stephen Ellis, M.D., professor of medicine and director of interventional cardiology at Cleveland Clinic, discusses t
Gore Tigris Vascular Stent, Health Canada approval, PAD, peripheral artery disease
News | Stents Peripheral| March 16, 2017
W. L. Gore & Associates Inc. recently announced the Health Canada approval of the Gore Tigris Vascular Stent, a...
Sponsored Content | Videos | Stents Bifurcation| March 06, 2017
This video, provided by Tryton, demonstrates the implantation of the Tryton Side Branch Stent.
Overlay Init